Basmisanil

Basmisanil
Clinical data
Other names	RG-1662; RO5186582
ATC code	None;
Identifiers
	IUPAC name (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone;
CAS Number	1159600-41-5;
PubChem CID	57336276;
ChemSpider	34500832;
UNII	788PET5SUA;
KEGG	D10863 ;
CompTox Dashboard (EPA)	DTXSID201032402 ;
Chemical and physical data
Formula	C21H20FN3O5S
Molar mass	445.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4;
	InChI InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3; Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N;

Basmisanil (INNTooltip International Nonproprietary Name; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α₅ subunit-containing GABA_A receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.^[1]^[2]^[3] As of June 2016, it is no longer studied for this purpose.^[4] It underwent a clinical trial for cognitive impairment in patients with schizophrenia.^[5]